KaloBios Pharmaceuticals slips on a Q2 miss

|About: KaloBios Pharmaceuticals (KBIO)|By:, SA News Editor

KaloBios Pharmaceuticals (KBIO -2.3%) slips after its Q2 loss came in greater than Street expectations.

The company attributes the loss to increased spending for clinical trial programs and higher SG&A expenses associated with being a public company.

Contract revenues were $15K, down from the prior-year period's $2.99M.